½ÃÀ庸°í¼­
»óǰÄÚµå
1594389

¾Ï Ä¡·á¿ë NDDS ½ÃÀå : À¯Çü, Åõ¿© ¹æ¹ý, Åõ¿© °æ·Î, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(2025-2030³â)

NDDS in Cancer Therapy Market by Type (Dendrimers, Liposomes, Micelles), Mode (Controlled Drug Delivery Systems, Modulated Drug Delivery Systems, Targeted Drug Delivery Systems), Route of Administration, Application, End-User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 193 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¾Ï Ä¡·á¿ë NDDS ½ÃÀåÀº 2023³â 104¾ï 1,000¸¸ ´Þ·¯·Î Æò°¡µÇ°í 2024³â¿¡´Â 117¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¬Æò±Õ 13.28% ¼ºÀåÇÏ¿© 2030³â¿¡´Â 249¾ï 4,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¾Ï Ä¡·áÀÇ »õ·Î¿î ¾à¹°Àü´Þ ½Ã½ºÅÛ(NDDS)Àº ¾Ï Ä¡·á¿Í °ü·ÃµÈ À¯È¿¼º, ¾ÈÀü¼º ¹× ȯÀÚ °æÇèÀ» °³¼±Çϱâ À§ÇÑ Çõ½ÅÀûÀÎ Á¢±Ù¹ýÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº ¸®Æ÷¼Ø, ³ª³ëÀÔÀÚ, ´ÜŬ·ÐÇ×ü¿Í °°Àº ÷´Ü ¹æ¹ýÀ» Æ÷ÇÔÇϸç, Á¾¾ç ºÎÀ§¿¡ Ç¥ÀûÈ­µÈ ¾à¹°Àü´Þ°ú Á¦¾îµÈ ¹æÃâÀ» ÅëÇØ ±âÁ¸ È­Çпä¹ý¿¡¼­ ÈçÈ÷ ³ªÅ¸³ª´Â ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­ÇÏ´Â µî NDDSÀÇ Çʿ伺ÀÌ ´ëµÎµÇ°í ÀÖ½À´Ï´Ù. NDDSÀÇ ÃÖÁ¾ ¿ëµµ´Â Á¤¹ÐÀÇ·á°¡ Á¡Á¡ ´õ ¿ì¼±¼øÀ§°¡ µÇ°í ÀÖ´Â º´¿ø, Áø·á¼Ò, ¿¬±¸±â°ü µî ´Ù¾çÇÑ ÃÖÁ¾ ¿ëµµ ºÐ¾ß·Î È®´ëµÇ°í ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ[2023] 104¾ï 1,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ[2024] 117¾ï 5,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ[2030] 249¾ï 4,000¸¸ ´Þ·¯
CAGR(%) 13.28%

¾Ï Ä¡·á¿ë NDDSÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î´Â ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ ±â¼ú ¹ßÀü, ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, Á¦¾à»çÀÇ R&D ÅõÀÚ Áõ°¡ µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Çõ½ÅÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ Áö¿ø°ú »ý¹°ÇÐÀû Á¦Á¦ÀÇ Ã¤Åà Áõ°¡µµ ½ÃÀå ÀáÀç·ÂÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù. ±×·¯³ª ³ôÀº °³¹ß ºñ¿ë, º¹ÀâÇÑ ±ÔÁ¦ °æ·Î, Á¦Ç° Á¦Á¶ ¹× °ËÁõ¿¡ µû¸¥ º¹À⼺ µîÀÇ µµÀü °úÁ¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù.

µ¶¼º À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖ´Â »ýºÐÇØ¼º ¹× »ýüÀûÇÕ¼ºÀÌ ³ôÀº Àü´Þ ½Ã½ºÅÛ °³¹ß¿¡ ÁýÁßÇÏ¸é ±âȸ¸¦ ÀâÀ» ¼ö ÀÖ½À´Ï´Ù. ¾à¹°Àü´ÞÀÇ Á¤È®¼ºÀ» ³ôÀ̱â À§ÇØ ÀΰøÁö´É°ú ¸Ó½Å·¯´×À» ÅëÇÕÇÏ´Â Çõ½Å¿¡ ÃÊÁ¡À» ¸ÂÃâ ¼öµµ ÀÖ½À´Ï´Ù. ȹ±âÀûÀÎ ¿¬±¸¸¦ À§ÇÑ Çмú ±â°ü°úÀÇ Çù·ÂÀº Àü·«Àû ÁøÀüÀ» °¡Á®¿Ã ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¹ÌÃæÁ· ÀÇ·á ¼ö¿ä°¡ ÀÖ´Â ½ÅÈï ½ÃÀåÀ¸·ÎÀÇ ÁøÃâÀº Å« ¼ºÀå ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù.

±×·¯³ª ±â¼úÀû º¹À⼺°ú Çõ½ÅÀûÀÎ ¼Ö·ç¼ÇÀÌ ½ÃÀå¿¡ Ãâ½ÃµÇ±â±îÁö °É¸®´Â ½Ã°£ÀÌ ±æ¾îÁö¸é¼­ ½ÃÀå ¼ºÀå¿¡ °É¸²µ¹ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹®Á¦¸¦ ±Øº¹Çϱâ À§ÇØ ÀÌÇØ°ü°èÀÚµéÀº Áö¼ÓÀûÀÎ ¿¬±¸°³¹ß¿¡ ÅõÀÚÇϰí, ±ÔÁ¦±â°ü°ú ±ä¹ÐÇÑ Çù·Â °ü°è¸¦ À¯ÁöÇÏ¿© ½ÂÀÎ ÀýÂ÷¸¦ °£¼ÒÈ­ÇØ¾ß ÇÕ´Ï´Ù. ½ÃÀåÀÇ ¿ªµ¿ÀûÀΠƯ¼ºÀº Ç×»ó ÀûÀÀÀ» ¿ä±¸Çϸç, Áö¼ÓÀûÀÎ ¼ºÀå°ú °æÀï·ÂÀ» À§Çؼ­´Â ±â¼ú Æ®·»µå¸¦ ¾Õ¼­°¡´Â °ÍÀÌ ¸Å¿ì Áß¿äÇÕ´Ï´Ù.

½ÃÀå ¿ªÇÐ : ºü¸£°Ô ÁøÈ­ÇÏ´Â ¾Ï Ä¡·á¿ë NDDS ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

¾Ï Ä¡·á¿ë NDDS ½ÃÀåÀº ¼ö¿ä¿Í °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ëÀ¸·Î ÀÎÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ º¯È­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«ÀûÀÎ ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ÃËÁø¿äÀÎ
    • Àü ¼¼°è ¾Ï À¯º´·ü »ó½Â
    • ¾à¹°ÀÇ ¿ëÇØµµ Çâ»ó ¹× µ¶¼º °¨¼Ò¸¦ À§ÇÑ NDDS¿¡ ´ëÇÑ ´ÏÁî Áõ´ë
    • ¾Ï Ä¡·á¿ë ½Å¾à Àü´Þ ½Ã½ºÅÛ °³¹ß ÅõÀÚ °¡¼ÓÈ­
  • ½ÃÀå ¾ïÁ¦¿äÀÎ
    • Á¦ÇÑÀûÀÎ Àνİú ¸·´ëÇÑ ºñ¿ë ÅõÀÔ
  • ½ÃÀå ±âȸ
    • À¯¸®ÇÑ »óȯ Á¤Ã¥°ú ÇÔ²² Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºê°¡ ºÎ»óÇϰí ÀÖ½À´Ï´Ù.
    • ÷´Ü Ç×¾ÏÁ¦ ³ª³ë ¾à¹°Àü´Þ ½Ã½ºÅÛ¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ¿¬±¸ Ȱµ¿
  • ½ÃÀå °úÁ¦
    • ¼÷·ÃµÇ°í °æÇèÀÌ Ç³ºÎÇÑ ÀÇ·á Àü¹®°¡ ºÎÁ·

Porter's Five Forces : ¾Ï Ä¡·á¿ë NDDS ½ÃÀåÀ» Ž»öÇϱâ À§ÇÑ Àü·«Àû µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲÀÇ °æÀï »óȲÀ» ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®¸¦ ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ¾Ï Ä¡·á¿ë NDDS ½ÃÀå¿¡¼­ÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ¾Ï Ä¡·á¿ë NDDS ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ÀÖ¾î ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : ¾Ï Ä¡·á¿ë NDDS ½ÃÀåÀÇ °æÀï »óȲ ÆÄ¾Ç

¾Ï Ä¡·á¿ë NDDS ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ ¾÷üµéÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü µî ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­, ÅëÇÕÀÇ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÀλçÀÌÆ®¸¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : ¾Ï Ä¡·á¿ë NDDS ½ÃÀå¿¡¼­ÀÇ ¾÷ü ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ¾Ï Ä¡·á¿ë NDDS ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ : ¾Ï Ä¡·á¿ë NDDS ½ÃÀå¿¡¼­ ¼º°øÇϱâ À§ÇÑ Àü·« ºÐ¼® ¹× ¼º°øÀÇ ±æ ã±â

¾Ï Ä¡·á ºÐ¾ßÀÇ NDDS ½ÃÀå Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ÀÇ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀº °æÀï ȯ°æÀÇ µµÀüÀ» ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ ü°è¸¦ ±¸ÃàÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï »óȲÀ» öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ÇâÈÄ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº ¾îµðÀΰ¡?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õÀÇ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå ¾Ï Ä¡·á¿ë NDDS ½ÃÀå : À¯Çüº°

  • µ§µå¸®¸Ó
  • ¸®Æ÷¼Ø
  • ¹Ì¼¿
  • ³ª³ëÀÔÀÚ

Á¦7Àå ¾Ï Ä¡·á¿ë NDDS ½ÃÀå ¸ðµåº°

  • Á¦¾î ¾à¹°Àü´Þ ½Ã½ºÅÛ
  • Á¶Àý ¾à¹°Àü´Þ ½Ã½ºÅÛ
  • Ç¥Àû ¾à¹°Àü´Þ ½Ã½ºÅÛ

Á¦8Àå ¾Ï Ä¡·á¿ë NDDS ½ÃÀå : Åõ¿© °æ·Îº°

  • ÁÖ»ç ¾à¹°Àü´Þ ½Ã½ºÅÛ
  • °æ±¸ ¾à¹°Àü´Þ ½Ã½ºÅÛ
  • Æó ¾à¹°Àü´Þ ½Ã½ºÅÛ
  • °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ

Á¦9Àå ¾Ï Ä¡·á¿ë NDDS ½ÃÀå : ¿ëµµº°

  • ³úÁ¾¾ç
  • À¯¹æ¾Ï
  • Æó¾Ï
  • ÃéÀå¾Ï

Á¦10Àå ¾Ï Ä¡·á¿ë NDDS ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
  • º´¿ø
  • Àü¹® Ŭ¸®´Ð

Á¦11Àå ¾Æ¸Þ¸®Ä«ÀÇ ¾Ï Ä¡·á¿ë NDDS ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦12Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¾Ï Ä¡·á¿ë NDDS ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦13Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¾Ï Ä¡·á¿ë NDDS ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®
  • ¿µ±¹

Á¦14Àå °æÀï »óȲ

  • ½ÃÀå Á¡À¯À² ºÐ¼® 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸®½ºÆ®

  • Abbott Laboratories
  • AstraZeneca
  • Boston Scientific Corporation
  • Cospheric LLC
  • Enable Injections
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Merit Medical Systems
  • MO-SCI Corporation
  • Novartis AG
  • Pacira BioSciences, Inc.
  • Pfizer Inc.
  • Samyang Holdings Corporation
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • West Pharmaceutical Services, Inc.
ksm 24.11.28

The NDDS in Cancer Therapy Market was valued at USD 10.41 billion in 2023, expected to reach USD 11.75 billion in 2024, and is projected to grow at a CAGR of 13.28%, to USD 24.94 billion by 2030.

The Novel Drug Delivery Systems (NDDS) in cancer therapy represent a transformative approach aimed at improving the efficacy, safety, and patient experience associated with cancer treatment. These systems encompass advanced methods like liposomes, nanoparticles, and monoclonal antibodies, offering targeted delivery and controlled release of therapeutic agents at tumor sites, minimizing the adverse effects commonly associated with traditional chemotherapy. The necessity for NDDS arises from the increasing prevalence of cancer and the compelling demand for more effective and less toxic treatment modalities. Its applications extend across various end-use sectors, including hospitals, clinics, and research institutes, where precision medicine is increasingly prioritized.

KEY MARKET STATISTICS
Base Year [2023] USD 10.41 billion
Estimated Year [2024] USD 11.75 billion
Forecast Year [2030] USD 24.94 billion
CAGR (%) 13.28%

Key factors driving the growth of NDDS in cancer therapy include technological advancements in drug delivery systems, growing awareness about personalized medicine, and increased R&D investments by pharmaceutical companies. Additionally, regulatory support for innovative treatment options and the rising adoption of biologics are enhancing the market potential. However, the market faces challenges such as high development costs, complex regulatory pathways, and the intricacies involved in product manufacturing and validation.

Opportunities can be seized by focusing on the development of biodegradable and bio-compatible delivery systems, which are anticipated to mitigate risks of toxicity. Innovation could be directed towards the integration of artificial intelligence and machine learning to enhance precision in drug delivery. Collaborations with academic institutions for groundbreaking research can provide strategic advancements. Furthermore, expanding into emerging markets with unmet medical needs presents vast growth potential.

However, the market's growth could be hindered by technological complexities and the prolonged time-to-market for innovative solutions. To navigate these challenges, stakeholders should invest in continuous research and development, while also maintaining strong collaborations with regulatory bodies to streamline approval processes. The dynamic nature of the market requires constant adaptation, and staying ahead of technological trends will be crucial for sustained growth and competitiveness.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving NDDS in Cancer Therapy Market

The NDDS in Cancer Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of cancer across the globe
    • Increasing need of NDDS to imrove drug solubility and reduce toxicity
    • Accelerating investments for development of novel drug delivery systems for cancer
  • Market Restraints
    • Limited awareness and involvement of huge cost
  • Market Opportunities
    • Emerging government initiatives coupled with favorable reimbursement policies
    • Ongoing research activities for advanced anti-cancer nano drug delivery system
  • Market Challenges
    • Dearth of skilled and experienced medical professionals

Porter's Five Forces: A Strategic Tool for Navigating the NDDS in Cancer Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the NDDS in Cancer Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the NDDS in Cancer Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the NDDS in Cancer Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the NDDS in Cancer Therapy Market

A detailed market share analysis in the NDDS in Cancer Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the NDDS in Cancer Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the NDDS in Cancer Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the NDDS in Cancer Therapy Market

A strategic analysis of the NDDS in Cancer Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the NDDS in Cancer Therapy Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AstraZeneca, Boston Scientific Corporation, Cospheric LLC, Enable Injections, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Merit Medical Systems, MO-SCI Corporation, Novartis AG, Pacira BioSciences, Inc., Pfizer Inc., Samyang Holdings Corporation, Sanofi S.A., Teva Pharmaceutical Industries Ltd., and West Pharmaceutical Services, Inc..

Market Segmentation & Coverage

This research report categorizes the NDDS in Cancer Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Dendrimers, Liposomes, Micelles, and Nanoparticles.
  • Based on Mode, market is studied across Controlled Drug Delivery Systems, Modulated Drug Delivery Systems, and Targeted Drug Delivery Systems.
  • Based on Route of Administration, market is studied across Injectable Drug Delivery Systems, Oral Drug Delivery Systems, Pulmonary Drug Delivery Systems, and Transdermal Drug Delivery Systems.
  • Based on Application, market is studied across Brain Cancer, Breast Cancer, Lung Cancer, and Pancreatic Cancer.
  • Based on End-User, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of cancer across the globe
      • 5.1.1.2. Increasing need of NDDS to imrove drug solubility and reduce toxicity
      • 5.1.1.3. Accelerating investments for development of novel drug delivery systems for cancer
    • 5.1.2. Restraints
      • 5.1.2.1. Limited awareness and involvement of huge cost
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging government initiatives coupled with favorable reimbursement policies
      • 5.1.3.2. Ongoing research activities for advanced anti-cancer nano drug delivery system
    • 5.1.4. Challenges
      • 5.1.4.1. Dearth of skilled and experienced medical professionals
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. NDDS in Cancer Therapy Market, by Type

  • 6.1. Introduction
  • 6.2. Dendrimers
  • 6.3. Liposomes
  • 6.4. Micelles
  • 6.5. Nanoparticles

7. NDDS in Cancer Therapy Market, by Mode

  • 7.1. Introduction
  • 7.2. Controlled Drug Delivery Systems
  • 7.3. Modulated Drug Delivery Systems
  • 7.4. Targeted Drug Delivery Systems

8. NDDS in Cancer Therapy Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Injectable Drug Delivery Systems
  • 8.3. Oral Drug Delivery Systems
  • 8.4. Pulmonary Drug Delivery Systems
  • 8.5. Transdermal Drug Delivery Systems

9. NDDS in Cancer Therapy Market, by Application

  • 9.1. Introduction
  • 9.2. Brain Cancer
  • 9.3. Breast Cancer
  • 9.4. Lung Cancer
  • 9.5. Pancreatic Cancer

10. NDDS in Cancer Therapy Market, by End-User

  • 10.1. Introduction
  • 10.2. Ambulatory Surgical Centers
  • 10.3. Hospitals
  • 10.4. Specialty Clinics

11. Americas NDDS in Cancer Therapy Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific NDDS in Cancer Therapy Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa NDDS in Cancer Therapy Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AstraZeneca
  • 3. Boston Scientific Corporation
  • 4. Cospheric LLC
  • 5. Enable Injections
  • 6. GlaxoSmithKline PLC
  • 7. Johnson & Johnson Services, Inc.
  • 8. Merck & Co., Inc.
  • 9. Merit Medical Systems
  • 10. MO-SCI Corporation
  • 11. Novartis AG
  • 12. Pacira BioSciences, Inc.
  • 13. Pfizer Inc.
  • 14. Samyang Holdings Corporation
  • 15. Sanofi S.A.
  • 16. Teva Pharmaceutical Industries Ltd.
  • 17. West Pharmaceutical Services, Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦